Dancann Pharma A/S

DANCAN

DK0061410487

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 18:00:00 2024-05-28 EDT			5-day change	1st Jan Change
0.0422 ^DKK	-18.53%		-35.67%	+40.67%

03-29	Dancann Pharma Plans Up to DKK19 Million Rights Issue	MT
02-28	DanCann Pharma Notes Cannabis Legalization in Germany as Shares Surge	MT

Dancann Pharma A/S Announces Board Appointments

April 28, 2021 at 02:30 pm

Dancann Pharma A/S in an Annual General Meeting held on April 28, 2021 elected Christian Carlsen as a new additional board member.

Latest news about Dancann Pharma A/S

Dancann Pharma Plans Up to DKK19 Million Rights Issue	03-29	MT
DanCann Pharma Notes Cannabis Legalization in Germany as Shares Surge	02-28	MT
Dancann Pharma A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
Dancann Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Dancann Pharma A/S Provides Revenue Guidance for the Financial Year 2025	12-20	CI
Dancann Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-30	CI
DanCann Pharma Issues New Shares For Debt Conversion	11-23	MT
DanCann Pharma Issues New Shares Following Debt Conversion	23-10-04	MT
DanCann Pharma Issues New Shares Upon Debt Conversion	23-09-26	MT
Dancann Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-31	CI
DanCann Mulls Sale of Production Facility Amid Shift in Business Strategy; Shares Plunge 13%	23-08-31	MT
DanCann Pharma Issues New Shares Upon Debt Conversion	23-08-21	MT
Dancann Pharma Lands DKK7 Million Debt Financing From Nordic Growth Fund; Shares Up 11%	23-07-18	MT
Dancann Pharma A/S' Pre-Validation Batches Meets European Standards, Paving the Path for Final Product Approval	23-06-01	CI
Dancann Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI
Dancann Pharma A/S Appoints Louise Bertelsen Forman as A New Additional Board Member	23-05-30	CI
Dancann Pharma Expects Final Danish Approval for Biotech Pharm1 Facility by End-summer	23-05-26	MT
Dancann Pharma in Advanced Talks for DKK12 Million Convertible Loan Deal	23-05-26	MT
Dancann Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-12	CI
Dancann Pharma A/S Auditor Raises 'Going Concern' Doubt	23-05-11	CI
DanCann Pharma to Distribute Prescription Cannabinoid-based Medications in Scandinavian Markets	23-05-09	MT
Dancann Pharma A/S Provides Positive Insight on Progress of Cannabis Bulk Product Approval	23-03-14	CI
Dancann Pharma A/S and Canngros Aps Open Office in Odense	23-02-23	CI
DanCann Pharma Hires New CFO	23-01-04	MT
DanCann Pharma A/S Appoints Peter Søndergaard as CFO	23-01-04	CI

Dancann Pharma A/S is a Denmark-based pharmaceutical biotechnology company powered by cannabinoids. The Company is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas. DanCann Pharma manufactures and distributes prescription drugs (Rx drugs) and over-the-counter drugs (OTCs), mainly focused on pain patients with alternative needs.

Sector

Biotechnology & Medical Research

Calendar

2024-08-28 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DANCANN PHARMA A/S	+40.67%	1.02M
VERTEX PHARMACEUTICALS INCORPORATED	+8.92%	114B
REGENERON PHARMACEUTICALS, INC.	+10.48%	105B
ARGENX SE	-1.83%	21.73B
BIONTECH SE	-6.45%	23.83B
GENMAB A/S	-10.39%	18.1B
WUXI APPTEC CO., LTD.	-42.36%	16.34B
BEIGENE, LTD.	-14.45%	16.13B
NEUROCRINE BIOSCIENCES, INC.	+3.76%	13.75B
SAREPTA THERAPEUTICS, INC.	+28.94%	11.76B

Bio Therapeutic Drugs